Literature DB >> 19185598

Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.

Jing Xu1, Shufeng Liu, Yihui Xu, Po Tien, Guangxia Gao.   

Abstract

Interferon-alpha (IFN-alpha) is the most commonly used therapeutics for the treatment of chronic viral infection. However, many viruses are resistant to IFN-alpha treatment to some degrees through encoding inhibitors of the IFN-alpha producing or signaling pathway. Multiple HCV viral proteins have been reported to be involved in IFN-alpha resistance. To develop a method to screen for factors that inhibit the antiviral activity of IFN-alpha, a mini-library of HCV genome was transduced into the Huh7 cells containing the HCV subgenomic replicon (CON1 HCV S2204I) and screened for the factor that rendered the cells more resistant to IFN-alpha treatment. A fragment of nonstructural protein 4B (NS4B), named tNS4B, was isolated. Expression of tNS4B or the full-length NS4B in CON1 HCV S2204I or naïve Huh7 cells inhibited the protection of the cells by IFN-alpha treatment from vesicular stomatitis virus (VSV) infection. In Huh7 cells expressing NS4B or tNS4B, IFN-alpha-induced phosphorylation levels of signal transducer and activator of transcription 1 (STAT1) were reduced. Furthermore, expression of NS4B reduced IFN-alpha-induced expression levels of type I interferon receptor and a reporter driven by the ISRE promoter. In conclusion, we have developed a method to screen for IFN-alpha resistance factors and identified HCV NS4B as such a factor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185598     DOI: 10.1016/j.virusres.2009.01.001

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

Review 1.  Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Authors:  Abhik Saha; Rajeev Kaul; Masanao Murakami; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

2.  Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.

Authors:  James Lara; Guoliang Xia; Mike Purdy; Yury Khudyakov
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

3.  Establishment of stable Huh-7 cell lines expressing various hepatitis C virus genotype 3a protein: an in-vitro testing system for novel anti-HCV drugs.

Authors:  Sadia Butt; Muhammad Idrees; Irshad-Ur Rehman; Liaqat Ali; Abrar Hussain; Muhammad Ali; Naveed Ahmed; Sana Saleem; Madiha Fayyaz
Journal:  Genet Vaccines Ther       Date:  2011-06-28

Review 4.  Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?

Authors:  Daniele Lapa; Anna Rosa Garbuglia; Maria Rosaria Capobianchi; Paola Del Porto
Journal:  Cells       Date:  2019-04-03       Impact factor: 6.600

Review 5.  Early IFN type I response: Learning from microbial evasion strategies.

Authors:  Eliana M Coccia; Angela Battistini
Journal:  Semin Immunol       Date:  2015-04-11       Impact factor: 11.130

Review 6.  The role of HCV proteins on treatment outcomes.

Authors:  Kattareeya Kumthip; Niwat Maneekarn
Journal:  Virol J       Date:  2015-12-15       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.